{
    "clinical_study": {
        "@rank": "157886", 
        "arm_group": [
            {
                "arm_group_label": "Kovacaine Mist, 3 sprays unilateral", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3% and oxymetazoline HCl 0.05%"
            }, 
            {
                "arm_group_label": "Tetracaine Only, 3 sprays unilateral", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3%"
            }, 
            {
                "arm_group_label": "Placebo, 3 sprays unilateral", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and\n      Placebo for inducing pulpal anesthesia of the maxillary teeth in adults."
        }, 
        "brief_title": "Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Anesthesia", 
        "detailed_description": {
            "textblock": "The study will employ a multi-center, randomized, double-blind, placebo-controlled,\n      parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered\n      intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary\n      right second premolar to maxillary left second premolar) sufficient to allow completion of\n      the Study Dental Procedure.\n\n      A total of 140 subjects, randomized 2:2:1 (Kovacaine Mist:Tetracaine alone:Placebo) will be\n      enrolled to achieve 125 completed subjects; a total of 50 Kovacaine Mist subjects, 50\n      tetracaine alone subjects and 25 placebo subjects.  Recruitment will be from diverse dental\n      patient populations.   At the two study sites, a balanced enrollment of 70 subjects each is\n      planned to allow for a potential 10% drop-out rate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 years of age or older.\n\n          -  Need for an operative restorative dental procedure requiring local anesthesia for a\n             single vital maxillary tooth (other than a maxillary first, second, or third molar)\n             with no evidence of pulpal pathology.\n\n          -  Normal lip, nose, eyelid, and cheek sensation.\n\n          -  Able to understand and sign the study informed consent document, communicate with the\n             investigators, and understand and comply with the requirements of the protocol.\n\n          -  Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.\n\n          -  Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.\n\n          -  Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated\n             diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.\n\n        Exclusion Criteria:\n\n          -  Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).\n\n          -  Inadequately controlled active thyroid disease of any type.\n\n          -  Frequent nose bleeds (\u2265 5 per month).\n\n          -  Having received dental care requiring a local anesthetic within the last 24 hours.\n\n          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local\n             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).\n\n          -  History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or\n             sulfite preservatives.\n\n          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.\n\n          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant.\n             (Females of child-bearing potential will be required to take a urine pregnancy test\n             on the day of, but prior to, study drug administration to rule out pregnancy.)\n\n          -  Having received any investigational drug and/or participation in any clinical trial\n             within 30 days prior to study participation.\n\n          -  Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other\n             nasal or oral decongestant on the day of the study procedure.\n\n          -  History of congenital or idiopathic methemoglobinemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660893", 
            "org_study_id": "SR 3-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Kovacaine Mist, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Tetracaine HCl 3% and oxymetazoline HCl 0.05%", 
                "intervention_type": "Drug", 
                "other_name": "Kovacaine Mist"
            }, 
            {
                "arm_group_label": "Tetracaine Only, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Tetracaine HCl 3%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Oxymetazoline", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "operative", 
            "dental procedure"
        ], 
        "lastchanged_date": "October 1, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20740"
                    }, 
                    "name": "University of Maryland, Baltimore"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Family and Cosmetic Dentistry"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Jean Brown Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Paul A. Moore, DMD/PhD/MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).", 
            "safety_issue": "No", 
            "time_frame": "at 15 minutes with a 3 minute window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intraoral soft-tissue anesthesia (yes/no) and the time to onset and duration of such soft-tissue anesthesia.", 
                "safety_issue": "No", 
                "time_frame": "at 15 minutes with a 3 minute window"
            }, 
            {
                "measure": "Heart Rate higher than 125 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Heart Rate lower than 50 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Increase from baseline in Systolic blood pressure greater than or equal to 25 mm Hg and to a value higher than 140 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Systolic blood pressure greater than or equal to 15 mm Hg and to a value lower than 90 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Increase from baseline in Diastolic blood pressure greater than or equal to 15 mm Hg and to a value higher than 95 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Diastolic blood pressure greater than or equal to 10 mm Hg and to a value lower than 50 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Maximum change from baseline in Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }, 
            {
                "measure": "The profile over time of Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }, 
            {
                "measure": "Alcohol Sniff Test", 
                "safety_issue": "Yes", 
                "time_frame": "administered at approximately 24 hours after drug administration"
            }
        ], 
        "source": "St. Renatus, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Triligent International", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Tegra Analytics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Renatus, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}